• Science & evidence
• Wellness
• Clinical trials
• FDA

Taking a shot at the King: Retatrutide vs Everyone

By Peptide Policy Watch staff · Published November 13, 2026 · 7 min read · 7 sources, 7 checked at the source

ObesityWeek 2026 opens Saturday, November 14. The poster list looks like a challenger lineup: monthly peptides, a wave of amylin data, and early five-hormone molecules, all measured against Lilly's retatrutide.

That's the through-line on the program, which runs through Tuesday, November 17, outside Washington, D.C. [V] Retatrutide is still in phase 3, and Lilly plans to file with FDA in the first quarter of 2027, but it's already the king of the pipeline — the bar everyone else is lining up against. [V] Here's who's taking a shot, and how far along each one is.

Facts are as of November 13, 2026. The program lists poster titles; results come out when each poster is presented. Sources, with retrieval dates, are at the bottom.

The king of the pipeline

Retatrutide, Lilly's triple-hormone peptide, is still in phase 3, and Lilly says it plans to file with FDA in the first quarter of 2027. [V] It isn't approved yet, and FDA has said it can't be compounded. [V] Even so, it's already the standard other labs measure against.

Retatrutide itself has human news on the program: a poster on participant experiences in the TRIUMPH-1 trial. [V] For the human trial data so far, see the retatrutide evidence page and the recent knee osteoarthritis results.

Taking a shot

A poster from the Indiana Biosciences Research Institute and Volari Therapeutics says a quintuple agonist hitting GLP-1, GIP, glucagon, amylin and calcitonin receptors drove more weight loss than retatrutide in rats. [V] Ascletis says its ASC37 had a sixfold longer half-life than retatrutide in nonhuman primates. [V] Dong-A ST says DA-1726 matched retatrutide's weight loss with a different metabolic profile. [V]

These are animal results, the normal starting line for any drug, and head-to-head claims in rats often shift once people are studied. [V] [U] They're taking a shot at the current king. That doesn't mean they've passed it.

Monthly is the new weekly

Another way to take a shot is the calendar. Once a week already feels easy next to a daily pill or a daily pen. A medicine that only needs attention once a month could make staying on treatment easier, and that's the bet these companies are making. [U]

The headline poster on this front is Pfizer's. "Monthly Berobenatide (MET-097, PF-08653944) in Adults with Obesity: VESPER-3 1st Results" is set for Sunday, November 15, presented by Louis Aronne of Weill Cornell, with a second VESPER-3 poster on cardiometabolic risk markers the same afternoon. [V] Those are human trial results, which puts berobenatide ahead of most of the monthly field. [V]

Twice-monthly bofanglutide has two posters too, one from a US population and one from adults in China. [V] Everything else in this lane is earlier. Adocia will show AdoXLong, a platform it describes as enabling once-monthly incretins. [V] Daewoong has a monthly semaglutide depot tested for exposure in people and for weight effects in rats, plus a semaglutide microneedle patch. [V] Hansoh brings HS-20136-2, a monthly GLP-1/GIP/glucagon triple agonist at the discovery stage, and Alteogen a monthly incretin fusion protein aimed at weight regain. [V]

Weight regain after people stop is one of the field's sorest points, and a whole poster session is built around it. [V]

Amylin's big weekend

If monthly is about the schedule, amylin is about adding another hormone to the mix. Amylin is a hormone the pancreas releases alongside insulin, and FDA labeling for the amylin analogue pramlintide (Symlin) says it helps regulate appetite and slows how fast food leaves the stomach. [V]

Novo Nordisk has the deepest bench here. CagriSema, its cagrilintide-plus-semaglutide pairing, has REDEFINE 1 posters on results by starting BMI and obesity-related conditions, on early responders and weight-loss trajectories, and on day-to-day physical and psychosocial measures, plus REDEFINE 9 on muscle and lean mass. [V] Novo said in September it expects an FDA decision on CagriSema in the fourth quarter of 2026, which is covered in the CagriSema explainer. [V]

Lilly is building its own amylin lane. Eloralintide, an amylin receptor agonist, appears in a Lilly rat study where it was added on top of tirzepatide, and in a University of Pennsylvania poster that says it cut food intake and body weight without signs of illness behavior in animals. [V] Petrelintide gets a subgroup analysis of the phase 2 ZUPREME 1 trial and, in a Roche/Genentech poster, a study pairing it with enicepatide (ZYNERGY). [V]

• - Nov. 14–17ObesityWeek 2026 dates [V]
• - 4REDEFINE posters for CagriSema on the program [V]
• - 3early-stage posters measuring a new molecule against retatrutide [V]

Keeping the muscle

Losing weight without losing muscle is the other theme worth watching. Lilly has a phase 2 study of tirzepatide plus mibavademab against tirzepatide alone, and other teams bring myostatin-targeting peptides and antibodies. [V] Readers who lift will want this one. [U]

Pills, too

Lilly's oral GLP-1 pill Foundayo (orforglipron), a small molecule rather than a peptide, shows up across the program, including patient-reported convenience, reasons people started it, and what happened after a pause of a week or more in the ATTAIN-1 trial. [V] Novo has OASIS 4 data on oral semaglutide and daily activities. [V] The Foundayo approval explainer covers how it reached the market.

Where these stand with FDA

Most names here are investigational. Berobenatide, bofanglutide, eloralintide, petrelintide, ASC37, DA-1726, HS-20136-2 and the quintuple agonist have no FDA approval. [V] CagriSema is under FDA review, with a decision Novo expects this quarter. [V] Retatrutide isn't approved, and FDA has said it can't be compounded. [V] The approved options in the room are the ones you've heard of: semaglutide, tirzepatide and, since this year, Foundayo. [V]

A poster title is a promise of data, not the data itself. Until the posters go up, I can't tell you the numbers, and press summaries of conference posters can overstate early results. [U] The guide to reading a clinical trial listing is a good companion for the weekend.

Limits and unknowns

• I've read only the official poster titles and session listings; abstracts and numbers weren't public at press time. [U]
• The FDA's GLP-1 eye-risk (NAION) labeling change from November 9 applies across the approved class, and new class members will be watched for it too. [V] Details are in the NAION explainer.
• Animal and primate findings don't tell us how a drug performs in people. [V]

I'll update this page with results as the posters are presented, starting Saturday night.

Sources (retrieved November 13, 2026)

1. ObesityWeek 2026, "Posters Sorted by Poster Number," PDF dated October 30, 2026 (titles, presenters, sessions and times for Posters 027, 077, 089, 103, 104, 114, 225, 226, 229, 235, 242, 344, 354, 358, 359, 377, 384, 408, 415, 444, 445, 446, 503, 536, 843, 850) [V] — https://obesityweek.org/wp-content/uploads/2026/11/2026-10-30_OW26PostersByNumber.pdf
2. ObesityWeek 2026 session page, "Gut Peptides, Appetite Signaling & Novel Therapeutics," Saturday, November 14, 2026, 7:30–8:30 PM, Gaylord National Resort & Convention Center, Exhibit Hall BCD [V] — https://planion.events/e/tos/ow2026/sessions/2360247/
3. Novo Nordisk Science Hub, "Obesity Week (OW 2026)," Washington, US, 14–17 November 2026 (agenda of Novo presentations) [V] — https://sciencehub.novonordisk.com/congresses/ow2026.html
4. Novo Nordisk company announcements on CagriSema's FDA submission (December 18, 2025) and expected Q4 2026 decision (September 21, 2026), as cited in the CagriSema explainer [V] — https://peptidepolicywatch.com/2026/11/04/cagrisema-fda-decision-amylin-semaglutide-trials/
5. Eli Lilly, retatrutide TRIUMPH-4 and TRIUMPH-1-OA release with the plan to file in the first quarter of 2027, November 2026 [V] — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
6. FDA Drug Safety Communication on GLP-1 receptor agonist labeling (NAION), November 9, 2026 [V] — https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
7. FDA labeling for Symlin (pramlintide) on amylin's actions, as cited in the CagriSema explainer [V] — https://peptidepolicywatch.com/2026/11/04/cagrisema-fda-decision-amylin-semaglutide-trials/

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits